Molecular profiling of ADAM12 in human bladder cancer

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7359-7368

  Fröhlich, Camilla ^a   Albrechtsen, Reidar ^a   Dyrskjøt, Lars ^b   Rudkjær, Lise ^a   Ørntoft, Torben F ^b   Wewer, Ulla M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; BIOLOGICAL MARKER; DISINTEGRIN; PROTEIN ADAM10; PROTEIN ADAM12; PROTEIN ADAM8; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 33846190601     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1066     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-74.
3. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
4. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol 2004;14:277-86.
5. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61;109-18.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
7. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005;26:17-24.
8. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM. Cysteine-rich domain of human ADAM 12 (meltrin α) supports tumor cell adhesion. Am J Pathol 1999;154:1489-501.
9. Karan D, Lin FC, Bryan M, et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) inhuman prostatic adenocarcinomas. Int J Oncol 2003;23:1365-71.
10. Kodama T, Ikeda E, Okada A, et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004;165:1743-53.
11. Mazzocca A, Coppari R, De Franco R, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 2005;65:4728-38.
12. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res 2005;65:9312-9.
13. Wewer UM, Engvall E, Albrechtsen R. ADAM12: the long and the short of it. The ADAM family of proteases, proteases in biology and diseases. In: Hooper NM, Lendeckel U, editors. the Netherlands: Springer; 2005;123-46.
14. Gilpin BJ, Loechel F, Mattei MG, et al. A novel, secreted form of human ADAM 12 (meltrin α) provokes myogenesis in vivo. J Biol Chem 1998;273:157-66.
15. Hotoda N, Koike H, Sasagawa N, Ishiura S. A secreted form of human ADAM9 has an α-secretase activity for APP. Biochem Biophys Res Commun 2002;293:800-5.
16. Katagiri T, Harada Y, Emi M, Nakamura Y. Human metalloprotease/ disintegrin-like (MDC) gene: exon-intron organization and alternative splicing. Cytogenet Cell Genet 1995;68:39-44.
17. Roberts CM, Tani PH, Bridges LC, Laszik Z, Bowditch RD. MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes J Biol Chem 1999;274:29251-9.
18. Le Pabic H, Bonnier D, Wewer UM, et al. ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003;37:1056-66.
19. Lendeckel U, Kohl J, Arndt M, et al. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005;131:41-8.
20. Tian BL, Wen JM, Zhang M, et al. The expression of ADAM12 (meltrin α) in human giant cell tumours of bone. Mol Patnol 2002;55:394-7.
21. Kveiborg M, Frohlich C, Albrechtsen R, et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 2005;65:4754-61.
22. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-30.
23. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-6.
24. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-36.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
26. Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005;48:223-31.
27. Iba K, Albrechtsen R, Gilpin B, et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J Cell Biol 2000;149:1143-56.
28. Thodeti CK, Frohlich C, Nielsen CK, et al. Hierarchy of ADAM12 binding to integrins in tumor cells. Exp Cell Res 2005;309:438-50.
29. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000;278:511-5.
30. Kawaguchi N, Xu X, Tajima R, et al. ADAM 12 protease induces adipogenesis in transgenic mice Am J Pathol 2002;160:1895-903.
31. Sundberg C, Thodeti CK, Kveiborg M, et al. Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J Biol Chem 2004;279:51601-11.
32. Kong XT, Deng FM, Hu P, et al. Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases. J Cell Biol 2004;167:1195-204.
33. Olsburgh J, Harnden P, Weeks R, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 2003;199:41-9.
34. Truschel ST, Ruiz WG, Shulman T, et al. Primary uroepithelial cultures. A model system to analyze umbrella cell barrier function. J Biol Chem 1999;274:15020-9.
35. Wewer UM, Morgelin M, Holck P, et al. ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. J Biol Chem 2006;281:9418-22.
36. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
37. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-4.
38. Badalament RA, Hermansen DK, Kimmel M, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987;60:1423-7.
39. Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin North Am 2000;27:25-37.
40. Le Pabic H, L'Helgoualc'h A, Coutant A, et al. Involvement of the serine/threonine p70S6 kinase in TGF-β1-induced ADAM12 expression in cultured human hepatic stellate cells. J Hepatol 2005;43:1038-44.